S100A9 and cancer: CCL22 is found in a broad range of human cancers with potent pro-tumoral functions (34), while S100A8 and S100A9 are expressed by MDSCs in human CRC patients, are associated with the recruitment and immunosuppressive functions of MDSCs, and correlate with advanced CRC (35).